U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Gastroesophageal Junction Adenocarcinoma

MedGen UID:
1689127
•Concept ID:
C5204519
•
Neoplastic Process

Definition

Gastroesophageal junction adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Gastroesophageal Junction Adenocarcinoma

Professional guidelines

PubMed

Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.
Yang P, Pan T, Wang MK, Xiao MS, Zhang S, Liu S
Anticancer Drugs 2024 Aug 1;35(7):666-671. Epub 2024 Mar 22 doi: 10.1097/CAD.0000000000001607. PMID: 38527277

Recent clinical studies

Therapy

Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.
Yang P, Pan T, Wang MK, Xiao MS, Zhang S, Liu S
Anticancer Drugs 2024 Aug 1;35(7):666-671. Epub 2024 Mar 22 doi: 10.1097/CAD.0000000000001607. PMID: 38527277
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, Dhaene K, Wiechen K, Huber C, Maurus D, Arozullah A, Park JW, Schuler M, Al-Batran SE
Ann Oncol 2021 May;32(5):609-619. Epub 2021 Feb 19 doi: 10.1016/j.annonc.2021.02.005. PMID: 33610734
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV, Rosales M, Chung HC, H Yoon H, Shen L, Moehler M, Kang YK
Future Oncol 2021 Apr;17(10):1155-1164. Epub 2020 Dec 2 doi: 10.2217/fon-2020-1007. PMID: 33263418

Prognosis

Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.
Yang P, Pan T, Wang MK, Xiao MS, Zhang S, Liu S
Anticancer Drugs 2024 Aug 1;35(7):666-671. Epub 2024 Mar 22 doi: 10.1097/CAD.0000000000001607. PMID: 38527277
Lymph node involvement in advanced gastroesophageal junction adenocarcinoma.
Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, Rampone B, Roviello F
J Thorac Cardiovasc Surg 2007 Aug;134(2):378-85. doi: 10.1016/j.jtcvs.2007.03.034. PMID: 17662776

Clinical prediction guides

Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.
Yang P, Pan T, Wang MK, Xiao MS, Zhang S, Liu S
Anticancer Drugs 2024 Aug 1;35(7):666-671. Epub 2024 Mar 22 doi: 10.1097/CAD.0000000000001607. PMID: 38527277
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, Dhaene K, Wiechen K, Huber C, Maurus D, Arozullah A, Park JW, Schuler M, Al-Batran SE
Ann Oncol 2021 May;32(5):609-619. Epub 2021 Feb 19 doi: 10.1016/j.annonc.2021.02.005. PMID: 33610734

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...